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To the Editor: Postpartum cardiomyopathy (PPCM) is a disease of
unknown origin and exposes women to a high risk of mortality
after delivery despite optimal medical therapy (1).
Prolactin is up-regulated postpartally where it induces lactation
and promotes reshaping of the uterus. Prolactin exists in at least 2
biologically active forms with opposing effects. The physiological
full-length 23 kDa prolactin promotes angiogenesis and protects
endothelial cells whereas the cleaved 16 kDa derivate induces
endothelial cell apoptosis and disrupts capillary structures (2).
Recent data showed that oxidative stress promotes the postpartum
generation of 16 kDa prolactin, which is causally related to
PPCM. In turn, prolactin blockade with bromocriptine was
successful in preventing onset of PPCM in mice and in patients at
high risk for the disease (3). Here, we evaluated the efficacy of
bromocriptine for recovery in 2 patients with acute PPCM.
Case 1
A 32-year-old woman was admitted to a peripheral hospital with
heart failure (New York Heart Association [NYHA] functional
class III) 3 weeks after giving birth to a healthy child. She had no
pre-existing cardiac disease, exposure to cardiotoxic agents, or
positive family history of pregnancy-related heart disease. Echo-
cardiography revealed severe left ventricular (LV) dysfunction.
Postpartum cardiomyopathy was diagnosed, whereupon heart
failure therapy was initiated. However, the patient’s condition did
not improve, and she was transferred to our clinic 1 week later.
N-terminal pro-brain natriuretic peptide (NT-proBNP) was
markedly elevated (Table 1); creatine kinase (204 U/l), C-reactive
protein (11 mg/l), and S-creatinine (109 mol/l) were mildly
elevated while troponin T was within normal range. The patient
was breast feeding and displayed increased levels of total prolactin
(128 ng/ml; reference: 30 ng/ml). Sixteen kDa prolactin was
readily detectable by Western blot and was increased by 5- to
10-fold compared with that seen in 3 healthy nursing women.
Electrocardiography showed sinus tachycardia but was otherwise
normal. Echocardiography showed reduced LV function, LV
dilation (Table 1), and mitral valve regurgitation grade II to III
confirmed by cardiac magnetic resonance imaging.
Lactation was stopped by treatment with bromocriptine (5
mg/day, 2 weeks), which was followed by a rapid decrease of serum
prolactin levels (to 2.3 ng/ml after 2 weeks) and resulted in a
reduction of 16 kDa prolactin below detectable levels. In parallel,
LV function and heart failure symptoms improved, accompanied
by a decrease of NT-proBNP (Table 1). Bromocriptine was
continued for 6 weeks at 2.5 mg/day. Four months postpartum,
LV function and dimensions had further improved (Table 1), and
after 6 months, LV function had completely recovered (ejection
fraction: 60%, LV end-diastolic diameter 51 mm, LV end-systolic
diameter 34 mm) and mitral valve regurgitation was only mild. At
12 months’ follow-up, the patient was in NYHA functional class
I with normal LV systolic and diastolic function.
Case 2
The second patient (41 years old) collapsed after elective cesarian
section delivering twins. She was taken to the intensive care unit
with NYHA functional class IV, the diagnosis of PPCM was
made, and heart failure therapy and bromocriptine treatment were
initiated. Thereafter, her condition improved rapidly (Table 1).
Discussion
Experimental data implicate a causal role of the 16 kDa prolactin
for the development of PPCM in mice, which was prevented by
suppression of prolactin secretion with bromocriptine before the
onset of the disease (3). Similarly, in a small pilot study, bro-
mocriptine prevented the recurrence of PPCM in a subsequent
pregnancy in women who survived PPCM in the previous preg-
nancy (3).
The present study reports 2 patients with acute PPCM in whom
bromocriptine treatment in addition to standard heart failure
therapy was associated with recovery and prevention of chronic
heart failure. This observation supports the notion that prolactin,
specifically its 16 kDa derivate, seems to play a crucial role not only
for the initiation but also for the progression of PPCM.
Experimental data suggest a major protective effect of bromocrip-
tine in PPCM by eliminating 16 kDa prolactin (3).
Previous reports attribute positive effects to bromocriptine treat-
ment in heart failure patients independent from PPCM (4). These 16
kDa prolactin-independent effects of bromocriptine may include the
elimination of the vasoconstrictive 23 kDa prolactin as well as direct
agonistic effects of bromocriptine on the dopamine DA2 receptors,
which may lower norepinephrine release, antagonize aldosterone, and
down-regulate type 1 angiotensin receptors (5,6). Therefore, benefi-
cial effects of bromocriptine on the sympathetic nervous system and
on hemodynamics may combine to assist recovery of PPCM patients.
However, both patients described here obtained beta-blockers
and angiotensin-converting enzyme inhibitors before and during
bromocriptine therapy, which may limit the mentioned effects of
bromocriptine on sympathetic tone and hemodynamics. Neverthe-
less, it is possible that a multifactorial role of bromocriptine might
ultimately account for its beneficial effects.
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As a limitation to the present observation, it should be noted
that some PPCM patients recover spontaneously (1). Therefore, a
controlled randomized study is needed in order to determine the
true value of bromocriptine as a specific novel therapy for PPCM.
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Letters to the Editor
Exercise in Chronic Heart Failure:
Does it Need to Be
“Anti-Remodeling”?
From their analysis, Haykowsky et al. (1) conclude that combined
aerobic and strength training provides no anti-remodeling benefit
in patients with chronic heart failure (CHF). The fact that the
latter studies all date from the last 5 years is not highlighted.
Systematic prescription of beta-blockers in recent trials might have
obscured additional anti-remodeling effects of combined exercise
training.
The relevance attributed to the 3% increase in left ventricular
ejection fraction in the accompanying editorial is surprising (2).
Patients treated with cardiac resynchronization therapy (CRT)
would typically be classified as nonresponders based on this modest
improvement. Furthermore, increased blood pressure is called upon
by Haykowsky et al. (1) to explain the lack of anti-remodeling effects
of combined exercise training. In fact, McKelvie et al. (3) showed a
lower rate–pressure product when patients with CHF performed
leg press versus aerobic cycling at comparable exercise intensity.
Finally, Rubin (2) mentions being unaware of exercise training
studies in CRT-treated patients. We recently showed that the
combination of endurance training with CRT is highly effective in
terms of exercise capacity (4).
Endurance training in patients with CHF concentrates on peak
exercise capacity and apparently also provides modest anti-
remodeling effects (1). However, disabled CHF patients are also
likely to benefit from dynamic resistive exercise. To a large extent,
quality of life in this population depends on engagement in daily
life activity, which does not demand peak aerobic performance.
Table 1
Time Course of NYHA Functional Class,
NT-proBNP Levels, and Echocardiographic Data of Cases 1 and 2
Case 1 Case 2
Baseline
2
Weeks
4
Months Baseline
2
Weeks
4
Months
NYHA functional class III II II IV III I
NT-proBNP (ng/l) 10,611 3,142 n.d. 14,933 462 97
LVEDD (mm) 60 59 51 55 53 43
LVESD (mm) 53 49 34 39 39 32
Fractional shortening (%) 12 17 33 19 26 25
Ejection fraction (%) 17 29 57 30 50 49
Heart rate (beats/min) 123 79 71 119 94 48
LVEDD  left ventricular end-diastolic diameter; LVESD  left ventricular end-systolic diameter; n.d.  not determined; NT-proBNP  N-terminal
pro-brain natriuretic peptide; NYHA  New York Heart Association.
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